Clinical Trials Logo
  1. Home
  2. Yaws
  3. NCT02344628

Comparison of Two Different Doses of Azithromycin for Treatment of Yaws

Yaws Clinical Trial

Official title:
Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin

Clinical Trial Summary

The study will be a single blinded, randomized, controlled open label non-inferiority phase III, trial with two parallel groups, conducted in Ghana and Papua New Guinea (PNG). The ultimate goal is to establish if a 20mg/kg dose of azithromycin is as effective as a 30mg/kg dose in the treatment of yaws. Approximately 600 clinically and serologically diagnosed yaws patients will be included in the study. Patients will be randomized to receive treatment with the two antibiotic regimens as follow: (i) Regimen I (AZT20): Single oral dose of 20 mg/kg azithromycin (ii) Regimen II (AZT30): Single oral dose of 30 mg/kg azithromycin. The follow-up period of patients will be 6 months. Assessments before, during and after the antibiotic treatment will include full medical history, clinical assessment of the lesion and, laboratory investigations. The primary efficacy parameters are healing of the lesion at 4 weeks and a four-fold decline in RPR titre at 6 months after start of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02344628
Study type Interventional
Source London School of Hygiene and Tropical Medicine
Contact
Status Completed
Phase Phase 3
Start date June 2015
Completion date December 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01382004 - Single-dose Azithromycin for the Treatment of Yaws Phase 3
Completed NCT03664063 - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT04453124 - An Accessible Low-cost Plant Treatment for Cutaneous Ulcers Phase 2
Completed NCT01955252 - Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Phase 3
Active, not recruiting NCT04753788 - Evaluation of a LAMP Assay for T. Pallidum. Pertenue
Recruiting NCT05764876 - Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) Phase 3
Recruiting NCT03683745 - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Completed NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease Phase 4
Completed NCT01841203 - Dual Point-of-care Test for the Diagnosis of Yaws N/A
Completed NCT03490123 - Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication Phase 4